Associations - KRAS G12V

KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	cetuximab Resistant: B - Late Trials cetuximab Resistant : B	cetuximab Resistant: B - Late Trials cetuximab Resistant : B
KRAS G12V	Ovarian Serous Adenocarcinoma	KRAS G12V	Ovarian Serous Adenocarcinoma	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2
KRAS G12V	Ovarian Cancer	KRAS G12V	Ovarian Cancer	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2
KRAS G12V	Solid Tumor	KRAS G12V	Solid Tumor	AFNT-211 Sensitive: C2 – Inclusion Criteria AFNT-211 Sensitive : C2	AFNT-211 Sensitive: C2 – Inclusion Criteria AFNT-211 Sensitive : C2
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3
KRAS G12V	Spindle Cell Sarcoma	KRAS G12V	Spindle Cell Sarcoma	BAL3833 Sensitive: C3 – Early Trials BAL3833 Sensitive : C3	BAL3833 Sensitive: C3 – Early Trials BAL3833 Sensitive : C3
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
KRAS G12V	Hepatocellular Cancer	KRAS G12V	Hepatocellular Cancer	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	VS-6766 Sensitive: C3 – Early Trials VS-6766 Sensitive : C3	VS-6766 Sensitive: C3 – Early Trials VS-6766 Sensitive : C3
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	RGX-202 Sensitive: C3 – Early Trials RGX-202 Sensitive : C3	RGX-202 Sensitive: C3 – Early Trials RGX-202 Sensitive : C3
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3
KRAS G12V	Lung Non-Squamous Non-Small Cell Cancer	KRAS G12V	Lung Non-Squamous Non-Small Cell Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	nivolumab + rigosertib Sensitive: C3 – Early Trials nivolumab + rigosertib Sensitive : C3	nivolumab + rigosertib Sensitive: C3 – Early Trials nivolumab + rigosertib Sensitive : C3
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3
KRAS G12V	Pancreatic Ductal Adenocarcinoma	KRAS G12V	Pancreatic Ductal Adenocarcinoma	gemcitabine + paclitaxel Resistant: C3 – Early Trials gemcitabine + paclitaxel Resistant : C3	gemcitabine + paclitaxel Resistant: C3 – Early Trials gemcitabine + paclitaxel Resistant : C3
KRAS G12V	Lung Adenocarcinoma	KRAS G12V	Lung Adenocarcinoma	osimertinib Resistant: C4 – Case Studies osimertinib Resistant : C4	osimertinib Resistant: C4 – Case Studies osimertinib Resistant : C4
KRAS G12V	Pancreatic Ductal Adenocarcinoma	KRAS G12V	Pancreatic Ductal Adenocarcinoma	anlotinib Sensitive: C4 – Case Studies anlotinib Sensitive : C4	anlotinib Sensitive: C4 – Case Studies anlotinib Sensitive : C4
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	AZ 628 Resistant: D – Preclinical AZ 628 Resistant : D	AZ 628 Resistant: D – Preclinical AZ 628 Resistant : D
KRAS G12V	Colon Cancer	KRAS G12V	Colon Cancer	CDK9 inhibitor Sensitive: D – Preclinical CDK9 inhibitor Sensitive : D	CDK9 inhibitor Sensitive: D – Preclinical CDK9 inhibitor Sensitive : D
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	selumetinib + AZ 628 Sensitive: D – Preclinical selumetinib + AZ 628 Sensitive : D	selumetinib + AZ 628 Sensitive: D – Preclinical selumetinib + AZ 628 Sensitive : D
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	selumetinib Resistant: D – Preclinical selumetinib Resistant : D	selumetinib Resistant: D – Preclinical selumetinib Resistant : D
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	sunitinib Resistant: D – Preclinical sunitinib Resistant : D	sunitinib Resistant: D – Preclinical sunitinib Resistant : D
KRAS G12V	Ovarian Cancer	KRAS G12V	Ovarian Cancer	trametinib Sensitive: D – Preclinical trametinib Sensitive : D	trametinib Sensitive: D – Preclinical trametinib Sensitive : D
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	ME-522 Sensitive: D – Preclinical ME-522 Sensitive : D	ME-522 Sensitive: D – Preclinical ME-522 Sensitive : D
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	pembrolizumab Sensitive: D – Preclinical pembrolizumab Sensitive : D	pembrolizumab Sensitive: D – Preclinical pembrolizumab Sensitive : D